Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3

Clin Pharmacol Ther. 2006 Mar;79(3):287-8. doi: 10.1016/j.clpt.2005.11.007.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Area Under Curve
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Celecoxib
  • Cyclooxygenase 2 Inhibitors / pharmacokinetics*
  • Cytochrome P-450 CYP2C9
  • Female
  • Genotype
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Pyrazoles / pharmacokinetics*
  • Sulfonamides / pharmacokinetics*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Pyrazoles
  • Sulfonamides
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Celecoxib